Intellia Therapeutics

Intellia Therapeutics develops novel, potentially curative treatments that use CRISPR-based gene editing to change DNA inside cells, either in the body (in vivo) or outside the body (ex vivo) from a patient or donor. The company is advancing late-stage in vivo CRISPR programs for hereditary angioedema and ATTR amyloidosis, and it employs proprietary technologies across a range of severe diseases. Intellia’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.